Evidence map›Paper›PMID 24521710›Full record

ArticleEpigenetics2014

A global profile of gene promoter methylation in treatment-naïve urothelial cancer.

Ilsiya Ibragimova, Essel Dulaimi, Michael J Slifker, David Y Chen, Robert G Uzzo, Paul Cairns

Open access · bronzeAbstract read
In one paragraph

Article in Epigenetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Anti-Cancer Effects and Tumor Marker Role of GlutathioneInternational journal of molecular sciences · 2021
    Article
  3. Review
  4. Article
  5. Article
  6. Epigenetic Alterations in Bladder Cancer.Current urology reports · 2018
    Review
  7. Article
  8. Promoter methylation analysis ofOncoTargets and therapy · 2018
    Article
  9. Clinical significance ofOncotarget · 2017
    Article
  10. Article
  11. Review
  12. Review
  13. [Effects of DNA methylation on ABO gene expression in leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016
    Article
  14. Article
  15. Article
  16. Article
  17. SWI/SNF chromatin remodeling complexes and cancer.American journal of medical genetics. Part C, Seminars in medical genetics · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ilsiya IbragimovaCancer Epigenetics Program; Fox Chase Cancer Center; Philadelphia PA, USA.
Essel DulaimiDepartment of Pathology; Fox Chase Cancer Center; Philadelphia PA, USA.
Michael J SlifkerDepartment of Biostatistics and Bioinformatics; Fox Chase Cancer Center; Philadelphia PA, USA.
David Y ChenDepartment of Urology; Fox Chase Cancer Center; Philadelphia PA, USA.
Robert G UzzoDepartment of Urology; Fox Chase Cancer Center; Philadelphia PA, USA.
Paul CairnsCancer Epigenetics Program; Fox Chase Cancer Center; Philadelphia PA, USA.
Fox Chase Cancer Center · USPhiladelphia University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The epigenetic alteration of aberrant hypermethylation in the promoter CpG island of a gene is associated with repression of transcription. In neoplastic cells, aberrant hypermethylation is well described as a mechanism of allele inactivation of particular genes with a tumor suppressor function. To investigate the role of aberrant hypermethylation in the biology and progression of urothelial cancer, we examined 101 urothelial (transitional cell) carcinomas (UC), broadly representative of the disease at presentation, with no prior immunotherapy, chemotherapy or radiotherapy, by Infinium HM27 containing 14,495 genes. The genome-wide signature of aberrant promoter hypermethylation in UC consisted of 729 genes significant by a Wilcoxon test, hypermethylated in a CpG island within 1 kb of the transcriptional start site and unmethylated in normal urothelium from aged individuals. We examined differences in gene methylation between the two main groups of UC: the 75% that are superficial, which often recur but rarely progress, and the 25% with muscle invasion and poor prognosis. We further examined pairwise comparisons of the pathologic subgroups of high or low grade, invasive or non-invasive (pTa), and high grade superficial or low grade superficial UC. Pathways analysis indicated over-representation of genes involved in cell adhesion or metabolism in muscle-invasive UC. Notably, the TET2 epigenetic regulator was one of only two genes more frequently methylated in superficial tumors and the sole gene in low grade UC. Other chromatin remodeling genes, MLL3 and ACTL6B, also showed aberrant hypermethylation. The Infinium methylation value for representative genes was verified by pyrosequencing. An available mRNA expression data set indicated many of the hypermethylated genes of interest to be downregulated in UC. Unsupervised clustering of the most differentially methylated genes distinguished muscle invasive from superficial UC. After filtering, cluster analysis showed a CpG Island Methylator Phenotype (CIMP)-like pattern of widespread methylation in 11 (11%) tumors. Nine of these 11 tumors had hypermethylation of TET2. Our analysis provides a basis for further studies of hypermethylation in the development and progression of UC.

Indexed as

DNA MethylationPromoter Regions, GeneticActinsAdultAgedAged, 80 and overCarcinoma, Transitional CellChromosomal Proteins, Non-HistoneCpG IslandsDioxygenasesDNA-Binding ProteinsEpigenesis, GeneticFemaleGenome, HumanHumansMaleActinsACTL6B protein, humanChromosomal Proteins, Non-HistoneDioxygenasesDNA-Binding ProteinsKMT2C protein, humanProto-Oncogene ProteinsTET2 protein, humanbladder cancerCIMPhypermethylationmethylomeMLL3TET2transitional cell carcinomaurothelial carcinoma

Identifiers

PMID24521710
PMCPMC4063835
OpenAlexW1993648003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.